These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 37336142)

  • 1. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
    Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
    JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
    Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
    Sho T; Suda G; Ohara M; Kohya R; Sasaki T; Yoshida S; Hosoda S; Ogawa K; Kitagataya T; Maehara O; Ohnishi S; Kawagishi N; Natsuizaka M; Nakai M; Baba M; Yamamoto Y; Tsukuda Y; Meguro T; Yamada R; Kobayashi T; Takagi T; Sakamoto N;
    Target Oncol; 2024 Sep; 19(5):769-778. PubMed ID: 39222223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
    Li J; Yang B; Teng Z; Liu Y; Li D; Qu X
    Front Immunol; 2024; 15():1430196. PubMed ID: 39355238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy for hepatocellular carcinoma.
    Rimassa L; Finn RS; Sangro B
    J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
    France NL; Blair HA
    Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
    J Hepatol; 2024 Aug; 81(2):258-264. PubMed ID: 38570034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma.
    Gordan JD; Keenan BP; Lim HC; Yarchoan M; Kelley RK
    Drugs; 2023 Aug; 83(12):1091-1109. PubMed ID: 37402062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials.
    Fulgenzi CAM; Scheiner B; Korolewicz J; Stikas CV; Gennari A; Vincenzi B; Openshaw MR; Silletta M; Pinter M; Cortellini A; Scotti L; D'Alessio A; Pinato DJ
    JHEP Rep; 2023 May; 5(5):100702. PubMed ID: 37025943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
    Liu TH; Shen YC; Cheng AL
    J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.